Recordati Pharma Germany company information, Employees & Contact Information

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Yahoo Finance

Amarin sells heart pill Vascepa's rights in Europe to Recordati amid restructuring bid Fierce Pharma

Recordati Rare Diseases touts new data in Cushing’s syndrome The Pharma Letter

White & Case advises on five percent share capital sale of Recordati through €600 accelerated bookbuild White & Case LLP

Recordati Announces CFO Resignation and Board Changes TipRanks

Italy’s Recordati Sees Tariff Volatility Fueling Dealmaking Bloomberg

Recordati Benefits From Cough & Cold Rebound Citeline News & Insights

Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU Yahoo Finance

Recordati runs with Jefferies upgrade, rewarded visibility on margins and turnover Il Sole 24 ORE

CVC exploring sale of drug maker Recordati, says rival CEO Private Equity Wire

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo Pharmaceutical Technology

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln Reuters

Recordati creates new head IP counsel role with major Zentiva hire JUVE Patent

Pharmaceutical sales of Recordati 2024, by region Statista

Amarin signs licensing deal with Recordati for VAZKEPA in Europe World Pharmaceutical Frontiers

Recordati buys rare disease drug Enjaymo in $825M Sanofi deal BioWorld MedTech

Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M MedCity News

Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal BioSpace

Recordati announces new three-year plan The Pharma Letter

In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo Fierce Pharma

FDA approves sNDA for Recordati’s Isturisa The Pharma Letter

Strong 2024 sales and earnings growth for Recordati The Pharma Letter

Recordati Updates on Share Buyback Program Execution TipRanks

Recordati Updates on Share Buyback Program TipRanks

Recordati: Isturisa® (Osilodrostat) Approved In The U.S. PR Newswire

KKR, TPG Express Interest in Italian Drugmaker Recordati Bloomberg

CVC Explores Options for €11 Billion Drugmaker Recordati Bloomberg

Ex-Novartis pituitary expert jumps to Recordati Rare Disease as CMO Fierce Biotech

RECORDATI RARE DISEASES: CARBAGLU® (Carglumic Acid) Tablets 200mg Receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia PR Newswire

Recordati to acquire EUSA Pharma for €750m, gaining 4 rare cancer drugs Fierce Pharma

Recordati acquires rights to Signifor and osilodrostat from Novartis Pharmaceutical Technology

Novartis offloads lagging endocrine drugs to Recordati for $390M Fierce Pharma

CVC Capital revs up rare disease ambitions with $3.5B Recordati buyout Fierce Pharma

Recordati and Novartis’ Isturisa Approved for Cushing’s Disease BioSpace

AstraZeneca's controversial castoffs continue with $300M heart-drug sale to Recordati Fierce Pharma

Amarin Enters Licensing Agreement with Recordati TipRanks

Andrea Recordati new commodore of the Yacht Club Costa Smeralda SuperYacht Times

Italy’s private equity weekly roundup. News from Recordati, Angelini, CVC, Omnia Technologies, Guala Closures, Investindustrial, and more – BeBeez International BeBeez International

Here's Why Shareholders May Consider Paying Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) CEO A Little More simplywall.st

Towards an Epistemology of Grand Strategy: Stereotype, Ideal Type, and the Dematerialization of the Concept The Strategy Bridge

FDA approves Recordati’s Cushing disease drug Isturisa PMLiVE

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® GlobeNewswire

AstraZeneca sells aging beta-blocker to Recordati for $300 million Reuters

Recordati snaps up Swiss pharma company Pro Farma PMLiVE

Recordati, Rossini sells 5% of its capital at a discount: here is the price and share price. The stock loses 6% firstonline.info

Recordati promotes Andrea Recordati to COO PMLiVE

CVC to buy Recordati for €3bn Financier Worldwide

Italy’s private equity weekly roundup. News from Gruppo Panini, Recordati, Basalt Infrastructures, Di Luccia& Partners, Fideuram, Investindustrial, Tages Capital, Xenon, Venchi – BeBeez International BeBeez International

Recordati — An international workforce dedicated to improving global healthcare Irish Examiner

CVC puts $9bn Recordati bid on hold as political uncertainty weighs| Gulf Times Gulf Times